Drug · CHEMBL163
RITONAVIR
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. RITONAVIR. Drugs and targets, record CHEMBL163. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL163
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Norvir, Ritonavir component of kaletra, Ritonavir component of paxlovid, Ritonavir component of technivie, Ritonavir component of viekirax, Ritonavir component of xiannuoxin, Ritonavir mylan
- ChEMBL
- Other names
- A-84538, ABBOTT-84538, ABT-538, Empetus, NSC-693184, Ritomune, Ritonavir related compounds mixture, Ritonavirum, Ritovir, Viekirax, Viriton
- ChEMBL
- Open Targets' highest stage
- Approval, for 5 of its 54 diseases, from ATC, ClinicalTrials.gov, DailyMed, EMA Human Drugs, PMDA and TTD
- Open Targets
Targets4
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| CYP3A4 | Cytochrome P450 3A | Cytochrome P450 3A inhibitor | INHIBITOR | https://conductscience.org/library/genes/1576 |
| CYP3A43 | Cytochrome P450 3A | Cytochrome P450 3A inhibitor | INHIBITOR | https://conductscience.org/library/genes/64816 |
| CYP3A5 | Cytochrome P450 3A | Cytochrome P450 3A inhibitor | INHIBITOR | https://conductscience.org/library/genes/1577 |
| CYP3A7 | Cytochrome P450 3A | Cytochrome P450 3A inhibitor | INHIBITOR | https://conductscience.org/library/genes/1551 |
Source ChEMBL
Diseases54
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| HIV infectious disease | Approval | ClinicalTrials.gov, DailyMed, EMA Human Drugs, PMDA and TTD | 298 | 279 | https://conductscience.org/library/drugs?q=MONDO_0005109 |
| hepatitis C virus infection | Approval | DailyMed and TTD | 66 | 64 | https://conductscience.org/library/drugs?q=MONDO_0005231 |
| COVID-19 | Phase 3 | ClinicalTrials.gov | 58 | 58 | https://conductscience.org/library/drugs?q=MONDO_0100096 |
| chronic hepatitis C virus infection | Approval | DailyMed and PMDA | 26 | 23 | https://conductscience.org/library/drugs?q=MONDO_0005354 |
| HIV-1 infection | Approval | ClinicalTrials.gov and DailyMed | 24 | 20 | https://conductscience.org/library/drugs?q=EFO_0000180 |
| tuberculosis | Phase 3 | ClinicalTrials.gov | 12 | 12 | https://conductscience.org/library/drugs?q=MONDO_0018076 |
| cirrhosis of liver | Phase 3 | ClinicalTrials.gov | 10 | 10 | https://conductscience.org/library/drugs?q=MONDO_0005155 |
| hepatitis B virus infection | Phase 3 | ClinicalTrials.gov | 6 | 6 | https://conductscience.org/library/drugs?q=MONDO_0005344 |
| AIDS | Phase 2 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0012268 |
| prostate cancer | Phase 2 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0008315 |
1 to 10 of 54Source Open Targets
See all 54 diseasesTrials860
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 4 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01061151 | Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries | Phase 3 | 3,747 | 2018-02-09 | lopinavir-ritonavir | A combination that names it | ClinicalTrials.gov |
| NCT00074581 | Preventing Sexual Transmission of HIV With Anti-HIV Drugs | Phase 3 | 3,526 | 2016-10-31 | ritonavir | Its name | ClinicalTrials.gov |
| NCT05047601 | A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection | Phase 2/3 | 2,954 | 2023-05-06 | ritonavir | Its name | ClinicalTrials.gov |
| NCT04960202 | EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19 | Phase 2/3 | 2,091 | 2023-02-09 | ritonavir | Its name | ClinicalTrials.gov |
| NCT00118898 | Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults | Phase 3 | 1,864 | 2011-01-10 | ritonavir | Its name | ClinicalTrials.gov |
| NCT00811954 | Comparative Study of Three NNRTI-Sparing HAART Regimens | Phase 3 | 1,814 | 2014-09-05 | ritonavir | Its name | ClinicalTrials.gov |
| NCT00342355 | Antiretroviral Therapy for Advanced HIV Disease in South Africa | Phase 4 | 1,771 | 2013-04-16 | ritonavir | Its name | ClinicalTrials.gov |
| NCT02219490 | A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection | Phase 3 | 1,596 | 2023-04-07 | ritonavir | Its name | ClinicalTrials.gov |
| NCT05011513 | Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR). | Phase 2/3 | 1,440 | 2023-08-14 | ritonavir | Its name | ClinicalTrials.gov |
| NCT02786537 | Study of Oral Treatments for Hepatitis C | Phase 4 | 1,275 | 2020-11-24 | ritonavir | Its name | ClinicalTrials.gov |
1 to 10 of 860
See all 860 trialsComparisons in its trials204
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Matched Treated: Long-term Disability vs Matched Untreated: Long-term Disability: Number of Participants With Any Long Term Disability (LTD) Claim: Matched Participants | 50 of 20,318 | 74 of 20,318 | 40,636 | NCT07072793 | Trial comparisons |
| Matched Treated: Short-term Disability vs Matched Untreated: Short-term Disability: Number of Participants With Any Short Term Disability (STD) Claim: Matched Participants | 1,343 of 20,065 | 1,848 of 20,065 | 40,130 | NCT07072793 | Trial comparisons |
| Matched Treated: Absence Eligibility vs Matched Untreated: Absence Eligibility: Number of Participants With Presence of Any Absence Records: Matched Participants | 1,255 of 1,909 | 1,331 of 1,909 | 3,818 | NCT07072793 | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Emergency Room (ER) Visits for Any Cause | 298 of 2,005 | 155 of 1,006 | 3,011 | NCT06291831 | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Hospitalization for Any Cause | 137 of 2,005 | 123 of 1,006 | 3,011 | NCT06291831 | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants Who Used Invasive Mechanical Ventilation (IMV) | 0 of 2,005 | 1 of 1,006 | 3,011 | NCT06291831 | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Supplemental Oxygen Usage | 21 of 2,005 | 11 of 1,006 | 3,011 | NCT06291831 | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With at Least 1 Pre-existing Comorbidities | 1,709 of 2,005 | 920 of 1,006 | 3,011 | NCT06291831 | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: deaths from any cause | 0 of 2,005 | 0 of 1,006 | 3,011 | NCT06291831 | Trial comparisons |
| Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Intensive Care Unit (ICU) Admission for Any Cause | 3 of 2,005 | 1 of 1,006 | 3,011 | NCT06291831 | Trial comparisons |
1 to 10 of 204
See all 204 comparisons in its trialsPapers from its trials718
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials9
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Verbal Learning | 3 | 0 | ConductCognition |
| Category Fluency | 1 | 0 | ConductCognition |
| Digit Span Test | 1 | 0 | ConductCognition |
| Matrix Reasoning | 1 | 0 | ConductCognition |
| Simple Reaction Time | 1 | 1 | ConductCognition |
| Stroop Color-Word Test | 1 | 0 | ConductCognition |
| Symbol Coding | 1 | 0 | ConductCognition |
| Symbol Scan Task | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL163
GET https://conductscience.org/api/drugs/v1/CHEMBL163/diseases?page=2